• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Organizing pneumonia after thoracic radiotherapy followed by anti‐PD‐1 antibody treatment for patients with lung cancer: Three case reports
【24h】

Organizing pneumonia after thoracic radiotherapy followed by anti‐PD‐1 antibody treatment for patients with lung cancer: Three case reports

机译：组织肺部放疗后的肺炎，然后是肺癌患者的抗PD-1抗体治疗：三个病例报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Anti-PD-1 antibodies and thoracic radiation therapy (TRT) generate adverse events, including pneumonitis. However, there is limited information about potential overlapping toxicity of anti-PD-1 antibodies administered after TRT. Herein, we report three cases. The first case was of a man in his 80s with squamous cell lung cancer (cT2aN0M0 stage IB). Twelve months after TRT, tumor regrowth was observed, and the patient was administered nivolumab. Twenty-four months after TRT, computed tomography (CT) showed organizing pneumonia (OP). The second case was of a man in his 70s with squamous cell lung cancer. He underwent surgery for pT3N1M0 stage IIIA; however, mediastinum lymph node metastasis developed. Therefore, he received TRT for the mediastinum lymph node metastasis. One month after the completion of TRT, nivolumab was administered. Two months after TRT, an OP diagnosis was made. The third case was of a man in his 60s with an unknown type of lung cancer. He received TRT for cT4N2M0 stage IIIB. Fourteen months after TRT, tumor regrowth was observed, thus, nivolumab was administered. Twenty-seven months after TRT, an OP diagnosis was made. These case reports draw attention to OP after TRT and anti-PD-1 antibody administration despite low V20. Careful follow-up of such patients is advised considering synergistic adverse events. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：抗PD-1抗体和胸部放射治疗（TRT）产生不良事件，包括肺炎。然而，有关TRT施用的抗PD-1抗体的潜在重叠毒性的有限信息。在此，我们报告了三个案例。第一种案例是他80s中的一个人，鳞状细胞肺癌（CT2AN0M0阶段IB）。 TRT后12个月，观察到肿瘤再生，患者施用Nivolumab。 TRT后二十四个月，计算断层扫描（CT）显示组织肺炎（OP）。第二种案例是他70岁的男人是鳞状细胞肺癌。他接受了PT3N1M0阶段IIIA的手术;然而，MapaseStinum淋巴结转移产生。因此，他接受了Mapystinum淋巴结转移的TRT。 TRT完成后一个月，施用Nivolumab。 TRT后两个月，进行了op诊断。第三个案例是他60岁的男人，具有未知类型的肺癌。他收到了CT4N2M0阶段IIIB的TRT。 TRT后十四个月，观察到肿瘤再生，因此，施用Nivolumab。 TRT后二十七个月，进行了op诊断。这些案例报告了TRT和抗PD-1抗体给药尽管低V20，请注意OP。考虑协同不良事件，建议仔细跟进这些患者。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号